Sun Pharmaceutical Industries to Acquire 100% Stake in Innovcare Lifesciences for Strategic Portfolio Boost
Sun Pharmaceutical Industries Limited has entered an agreement to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited, a company engaged in the business of marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products.The acquisition is designated as a strategic investment aimed at strengthening the product portfolio of Sun Pharma. The deal involves a cash consideration transaction, with the cost of acquisition stated at approximately Rs 271.2 Crores.
Sun Pharmaceutical Industries Limited intends to complete the acquisition by July 31, 2026. There are no governmental or regulatory approvals required for this transaction.
Innovcare Profile and Financials
Innovcare Lifesciences Private Limited is incorporated in Mumbai, Maharashtra, India, and operates within the Pharmaceuticals and Healthcare industry. The company specializes in marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products.The acquisition involves securing 100% of the outstanding shares of Innovcare.
Financial performance details for Innovcare over the past three fiscal years are as follows:
| Fiscal Year | Revenue (in INR Crores) |
|---|---|
| 2025-26 | 94.06 |
| 2024-25 | 86.09 |
| 2023-24 | 80.93 |
The transaction has been assessed as not being a related party transaction, and the promoter or promoter group does not hold any interest in the entity being acquired.
SUNPHARMA Stock Price Movement
Sun Pharmaceutical Industries Limited closed higher on Friday, gaining 0.85% to settle at ₹1838.3. The stock demonstrated robust trading activity, with over 2.13 million shares traded throughout the session as it touched a daily low of ₹1820.9.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.